Biotech Startups

Atlantic Fish develops bioengineering solutions, likely focusing on cellular agriculture or aquaculture applications based on team expertise in cell line development and bioprocess engineering.

4 investors

Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages. The company operates in the biotech and drug development space targeting these progressive, often fatal diseases.

4 investors

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease. The company leverages a proprietary discovery platform targeting immune-mediated disorders in pulmonary and systemic conditions.

4 investors

4 investors

Auransa is a clinical-stage, AI-native biopharma company that analyzes large human disease datasets to discover and develop novel cancer therapies. It works collaboratively with pharmaceutical companies and academic institutions to advance its drug discovery programs.

4 investors

Autopoiesis builds AI systems capable of autonomous scientific discovery, operating Aristotle, an AI research partner that assists scientists with hypothesis formation, evidence evaluation, and research direction decisions.

4 investors

AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform. The clinical-stage biopharmaceutical company creates autologous and allogeneic reprogrammable T-cell products and operates in both the US and Europe.

4 investors

Avenue Biosciences develops machine learning-enabled chemistry and software to accelerate the discovery and manufacturing of protein biologics for the biotechnology and therapeutics industry. The company combines high-throughput chemistry with computational tools to overcome production barriers in protein drug development.

4 investors

Averna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.

4 investors

Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.

4 investors

Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process. The company applies its drug discovery platform to create degraders as potential treatments for serious diseases.

4 investors

BACTA is an AI-powered bioproduction company that uses microorganisms to produce industrial ingredients such as astaxanthin for cosmetics, human nutrition, and animal nutrition markets.

4 investors

Bacto.bio is a biotechnology company developing a multidisciplinary pipeline, staffed by scientists, engineers, and other technical specialists.

4 investors

Basilard BioTech develops Celletto, a nanomechanical (mechanoporation) gene delivery platform that inserts genes directly into the nucleus of cells without viral vectors, aimed at cell and gene therapy (CGT) developers and manufacturers. The technology targets the gene-delivery bottleneck in engineering cell-based therapies, offering an alternative to viral, chemical, and physical delivery methods.

4 investors

Basking Biosciences develops therapeutics for thrombosis, vascular biology, and ischemic disease. The company focuses on stroke and cardiovascular applications.

4 investors

BBy develops a condensed breast milk product and process that preserves bioactive immunological properties for hospital distribution. The company serves hospitals, lactating mothers with supply challenges, and families needing access to safe, affordable breast milk nutrition.

4 investors

Beacon Therapeutics develops gene therapies for patients with serious diseases that lack or have limited treatment options, including investigational products like laru-zova for genetic conditions.

4 investors

BEIT provides physics-based computational approaches for drug discovery, embedding scientists with expertise in physics, mathematics, and engineering into pharmaceutical research programs.

4 investors

Beyond Barriers Therapeutics is a clinical-stage biotechnology company developing BBT-101, an intranasal therapeutic to reduce secondary effects from mild to moderate traumatic brain injuries. The company serves patients and medical professionals treating concussions, with support from the U.S. Department of Defense and NFLPA.

4 investors

Biftek develops a microorganism-based growth medium supplement for cultured meat production, offering a lower-cost alternative to fetal bovine serum. The product targets the cultivated meat industry, aiming to reduce the cost, water use, land use, and emissions associated with meat production.

4 investors

Biocartis develops molecular diagnostic testing systems for cancer, with a focus on enabling personalized medicine through rapid, in-house biomarker analysis. The company's Idylla Platform automates molecular testing to help clinicians and patients access treatment information quickly.

4 investors

BioEutectics develops eutectic chemical systems that serve industrial customers across multiple sectors, offering solutions ranging from direct solvent replacements to novel chemical capabilities.

4 investors

Bioflyte provides chemical and biological threat detection solutions for critical infrastructure and business operations, enabling organizations to monitor, identify and respond to bio/chem threats. The company serves government agencies, critical infrastructure operators, and other organizations responsible for security and safety.

4 investors

Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy. The company operates as a modern publicly traded entity and was acquired by Pfizer in May 2022 for approximately $13 billion.

4 investors